On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Eli Lilly ( NYSE: LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...

BDF-GESTION sold 4,149 shares of Eli Lilly ( LLY 0.58%) stock during the quarter. The estimated transaction value was $3.09 million, using the average unadjusted closing price for the quarter. After ...

Eli Lilly’s blockbuster drug Mounjaro has quickly become the market leader in the segment, thanks to its strong clinical ...

Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro ...

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multi-state battle to stop sales of replica ...

Cipla will market Eli Lilly’s diabetes and weight-loss drug Mounjaro as Yurpeak in India, enhancing accessibility and ...

Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...

Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the ...

Indian drugmaker Cipla Limited has entered into a strategic marketing and distribution agreement with US pharma major Eli ...